Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 45Unknown 16Not yet recruiting 5Terminated 4Withdrawn 3Recruiting 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 1Agnosia 1

Interventions

pembrolizumab 551Specimen Handling 465Carboplatin 441Magnetic Resonance Spectroscopy 430Cyclophosphamide 412Cisplatin 397Radiotherapy 313Gemcitabine 309Bevacizumab 307Paclitaxel 294Biopsy 261Drug Therapy 249Capecitabine 242Oxaliplatin 239fludarabine 237Nivolumab 224venetoclax 219Injections 213Docetaxel 205Fluorouracil 203Dexamethasone 187Radiosurgery 172Rituximab 158Pemetrexed 153Standard of Care 146durvalumab 143Leucovorin 139atezolizumab 138toripalimab 134tislelizumab 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Interventional × Ropivacaine × Clear all
NCT07092566 2026-01-20

R.E.C.K vs Exparel in Robotic Nephrectomy

Wake Forest University Health Sciences

Phase 3 Recruiting
170 enrolled
Genitourinary

Agnosia, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡